

[Handwritten signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

WEI *et al.*

Appl. No. 08/874,460

Filed: June 16, 1997

For: **Polynucleotides Encoding
Chemokine Beta-15 (As
Amended)**

Art Unit: 1646

Examiner: G. Draper

Atty. Docket: 1488.0420001/EKS/KLM



First Supplemental Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on October 6, 1997 in connection with the above-captioned application.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding clone of the captioned application are related to: 1) SEQ ID NO:15687 in copending U.S. Patent Application No. 08/196,363, filed February 15, 1994; 2) SEQ ID NO: 15706 in copending U.S. Patent Application No. 08/196,363, filed February 15, 1994; 3) SEQ ID NO: 15698 in copending U.S. Patent Application No. 08/196,363, filed February 15, 1994; and 4) SEQ ID NO: 15702 in copending U.S. Patent Application No. 08/196,363, filed February

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).


This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. Attached is our Check No. 22414 which includes the \$ 240.00 payment of the fee under 37 C.F.R. § 1.17(p).

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark

Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Kimberlin L. Morley
Attorney for Applicants
Registration No. 35,391

Date: July 28, 1998

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

2625
P:\USERS\KMORLEY\1488\042-1\supplids
SKGF Rev. 1/26/98